Literature DB >> 2003708

Long-term remission of chronic hepatitis B after alpha-interferon therapy.

J Korenman1, B Baker, J Waggoner, J E Everhart, A M Di Bisceglie, J H Hoofnagle.   

Abstract

OBJECTIVE: To evaluate whether remissions of chronic hepatitis B induced by alpha-interferon therapy are of long duration.
DESIGN: Cohort study.
SETTING: Clinical Center of the National Institutes of Health, a tertiary referral center. PATIENTS: Sixty-four patients with chronic hepatitis B were treated with alpha-interferon between 1984 and 1986. MAIN OUTCOME MEASURES: Patients were followed with frequent examinations and determinations of serum liver biochemical tests and hepatitis B virus (HBV) markers including hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA using blot hybridization and polymerase chain reaction.
RESULTS: Among 64 patients with chronic hepatitis B who were treated with alpha-interferon, 23 (36%) responded to treatment with loss of HBeAg and improvement in serum aminotransferases. All 23 have been followed for 3 to 7 years (mean, 4.3 years). During follow-up, 3 of 23 patients relapsed, with reappearance of HBeAg and abnormal serum aminotransferases, all within 1 year of therapy. The remaining 20 patients continued to have no detectable HBeAg or HBV DNA (using blot hybridization) in serum and to be asymptomatic for liver disease, although 3 had minimal elevations in serum aminotransferases. Thirteen patients (65%) became negative for HBsAg between 0.2 and 6 years (mean, 3 years) after loss of HBeAg. Although no patient had HBV DNA that was detectable by blot hybridization, the 7 patients who remained HBsAg positive all had HBV DNA in serum detected by polymerase chain reaction, but only 2 of 13 HBsAg-negative patients had viral genome using this method. Testing sequential samples indicated that HBV DNA detected by polymerase chain reaction usually disappeared at or around the time that test results for HBsAg became negative.
CONCLUSIONS: Remissions in chronic hepatitis B induced by alpha-interferon are of long duration and are followed, in most patients, by the loss of HBsAg and all evidence of residual virus replication.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2003708     DOI: 10.7326/0003-4819-114-8-629

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  52 in total

Review 1.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

2.  Hepatitis B.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-12

3.  Effects of interferon-alpha therapy on serum and liver HBV DNA in patients with chronic hepatitis B.

Authors:  S V Feinman; B Berris; R Sooknanan; B Fernandes; S Bojarski
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

Review 4.  Antiviral therapy and resistance with hepatitis B virus infection.

Authors:  Hans L Tillmann
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

5.  Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B.

Authors:  H J Flink; E H C J Buster; I Merican; F Nevens; G Kitis; J Cianciara; R A de Vries; B E Hansen; S W Schalm; H L A Janssen
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

Review 6.  Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies.

Authors:  Ralph Carmel; Mona Sarrai
Journal:  Curr Hematol Rep       Date:  2006-03

Review 7.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

8.  Interferon-alpha2b therapy is efficacious in Asian-Americans with chronic hepatitis B infection: a prospective controlled trial.

Authors:  P Martin; H W Hann; S Westerberg; S J Muñoz; R Rubin; W C Maddrey
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 9.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 10.  Current treatment indications and strategies in chronic hepatitis B virus infection.

Authors:  George V Papatheodoridis; Spilios Manolakopoulos; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.